Effectiveness of minimally invasive injectable modalities in the management of androgenetic alopecia among adults - A systematic review
Research Overview
Background and Scientific Context
Androgenetic alopecia (AGA), commonly referred to as genetic hair loss, is the most prevalent form of progressive hair thinning observed in adult men and women. It is characterized by patterned follicular miniaturization influenced by genetic predisposition, hormonal signaling, and hair cycle dysregulation. As understanding of hair biology and hair cycle phases has advanced, clinical interest has expanded beyond conventional topical and oral approaches toward minimally invasive injectable modalities that act at the scalp level.
This systematic review was undertaken to examine the evolving evidence base around injectable strategies explored for androgenetic alopecia, within the broader landscape of hair loss solutions and non-surgical interventions.
Study Objective
The objective of the review was to critically evaluate published clinical evidence related to minimally invasive injectable modalities used in adults with androgenetic alopecia. The review aimed to document study designs, assessment parameters, and reported observations related to hair density, follicular characteristics, and scalp environment, without positioning any approach as a definitive hair loss solution or permanent hair loss solution.
Methodology
A comprehensive literature search was conducted across multiple databases including PubMed/MEDLINE, Embase, PsycINFO, TRIP, Cochrane Library, and Cochrane Skin. Studies published between January 2000 and May 2023 were screened. Eligible studies included randomized controlled trials, non-randomized trials, cohort studies, and single-arm clinical investigations involving adult participants diagnosed with androgenetic alopecia.
Studies focusing on surgical hair replacement, hair transplantation, or hair replacement surgery were excluded to maintain focus on minimally invasive, non-surgical approaches relevant to contemporary hair care routines and scalp-based interventions.
Study Characteristics
Sixteen studies met the final inclusion criteria. These studies varied in sample size, duration, and assessment methodology, reflecting real-world clinical heterogeneity in the management of male hair loss and hair loss in women associated with genetic predisposition.
Assessment tools included phototrichograms, videomicroscopy, global photographic scores, hair pull testing, and patient-reported observations related to hair shedding and scalp condition. These tools are commonly used in clinical practice to monitor hair shedding vs hair fall and changes across different hair cycle phases.
Observational Outcomes
Across the reviewed studies, injectable modalities were explored in relation to observed changes in hair shaft diameter, follicular parameters, and scalp characteristics. Several studies documented variations in photographic scores and trichoscopic findings over the observation period, while others reported minimal or variable change.
Patient-reported outcomes frequently addressed subjective perceptions related to hair thinning, scalp comfort, and changes in visible hair appearance. These observations were recorded descriptively and were not interpreted as indicators of best hair loss treatment or comparative superiority.
Safety and Tolerability Reporting
Safety reporting across studies primarily focused on localized scalp responses, including transient discomfort, erythema, or sensitivity following injectable procedures. Serious adverse events were not a prominent finding. However, reporting consistency varied, highlighting the need for standardized safety documentation in future research evaluating anti hair loss solutions at the scalp level.
Interpretation and Research Implications
This review consolidates available human clinical evidence on minimally invasive injectable approaches within the broader context of hair loss and thinning associated with androgenetic alopecia. It highlights both the growing research interest in scalp-targeted injectable strategies and the limitations posed by heterogeneity in study design, outcome measures, and follow-up duration.
The paper does not advocate for any specific intervention as the best solution for hair loss, but instead provides a structured reference for clinicians and researchers examining evolving non-surgical approaches to managing genetic hair loss.
Disclaimer:
The research papers and clinical articles referenced on this website are peer-reviewed scientific publications authored by qualified medical professionals and represent the observations and conclusions of the respective authors, based on their individual clinical research.
These clinical references are provided for informational and educational purposes and should not be interpreted as promotional claims or outcome guarantees by QR678®. Consumers are advised to consult a qualified healthcare professional for medical interpretation or hair- or scalp-related concerns.
QR678®: SCIENCE Backed Research & Development Proprietary Product Technology
The QR678® research & development platform technology is a proprietary first-in-class technology. This science backed technology is giving rise to multiple products that arrest hair fall and address the thickness, density of hair follicles leading to greater coverage in hair loss. This R&D technology deals with multiple human hair growth related growth factors that are naturally present in our scalp making products derived from these completely natural. Research on this platform technology has resulted in this being awarded USA & Indian patents and has led to over 16+ clinical research papers being published with products derived from this unique technology. The hair growth factors penetrate deep into the scalp and provide nourishment to the scale. Unlike other treatments that contains harmful medication, products derived from QR678® are almost completely devoid of side effects.
HOW DOES IT WORK?
Benefits of choosing QR678®
QR678® ADVANTAGES
(Derived From Plants)
Quick & Effective (Single
Session in 10 Minutes)
Non Surgical
Success Rate
13+ Published Researched Clinical Trials Demonstrating Efficacy
LIFE CHANGING RESULTS
PRE TREATMENT
POST 6 SESSIONS
PRE TREATMENT
POST 6 SESSIONS
PRE TREATMENT
POST 6 SESSIONS
25 year old female from alopecia areata, was also diagnosed with hypothyroid. She achieved impressive results with QR678, a completely steroid-off treatment.
PRE TREATMENT
POST 6 SESSIONS
39 year old male suffering from male pattern hair loss for 15 years gained a significant amount of hair with QR678
MEDIA INTERVIEWS
TESTIMONIALS
HIGHLIGHTS IN MEDICAL CONFERENCES
CUTICON – December 2023
Dazzling moments at Cuticon 2023, Gujarat! QR678 took centre stage, earning accolades from top medical professionals.
QR678 made it’s presence felt at FADS (Face Aesthetics Dermatologists Society), the 7th International Conference held at Goa. Renowned dermatologists got QR678 Neo administered and shared their positive experience.
QR678® drew attention with an enlightening session and live demonstration at CDCON 2022 – a platform to challenge changing practices along the lines of Exploration and Innovation.
GLOBAL PRESENCE
OUR PARTNERS
FAQ'S
How is QR678® better than other hair fall treatments?
QR678® is a mixture of natural growth factors that are already present in the scalp and therefore it is completely safe to use on everybody. It has the right concentration of specific hair growth factors and QR678® does not have any side effects, is performed as an outpatient procedure and the results are visible within eight weeks of starting the treatment. You can listen for yourself what the patients say about QR678® hair fall treatment https://www.youtube.com/watch?v=pIvjpQgSsrc
How often do I need to repeat QR678® treatment?
QR678® injections are administered in 8-12 sessions in about 3-4 weeks apart. The results are visible after few weeks. Once you have achieved the desired results the injections need not be repeated unless the hair fall starts again. This is because QR678® make the hair follicles healthy. Get to know more about why QR678® is highly effective in treating hair fall and increasing hair growth. http://www.qr678.in/
What precautions should I take after QR678® treatment?
QR678® is a completely safe treatment without side effects and you can go about your daily routine after the sessions. The only care you need to take is to use a gentle shampoo not before the next day of the treatment and avoid scratching and rubbing the treating area. If you have any other problem then consult your dermatologist. https://www.youtube.com/watch?v=LNm2z3EGLxg
Can QR678® be used after hair transplant?
Yes, using QR678® after hair transplant produces very successful results. QR678® gives faster density and reduces the catagen loss of transplanted hair. The growth factors in QR678® Neo help in faster healing and activate the dormant follicles and thus
- Increase the viability of hair follicles
- Improve healing and repairing of tissue process
- Strengthen the inactive hair follicles and stimulate hair growth
- Improves the health of existing hair and they will become fuller and stronger
QR678® can be given in multiple treatment sessions after three to four weeks after successful hair transplant surgery. QR678® can also be used before the hair transplant surgery to reduce the area of transplant and improve the results.
How is QR678® better than PRP and stem cell hair fall treatment?
QR678® is a relatively new treatment for hair fall and hair regrowth but in the short time of its invention QR678® has proven to be more effective than PRP and stem cell treatment for reducing hair fall. QR678® produces longer lasting and better results and is completely safe and without any side effects. QR678® can help treat and rogenetic alopecia, female pattern hair loss, and hair loss because of chemotherapy, seborrheic dermatitis, and alopecia areata.
PRP and stem cell on the other hand do not have the specific concentration of required growth factors, they lack standardisation in terms of treatment protocols and preparation of the solution injected and lack good quality studies to prove their benefits. produce guaranteed results and can cause tightness and tenderness in scalp,
scar tissue formation, calcification of the injected points, and formation of scar tissues. Both processes are still under investigation and their results are still awaiting confirmation. Dr Rinky Kapoor of The Esthetic Clinics explains the difference between QR678® and stem cell here: https://www.youtube.com/watch?v=wgNihm8ciu4 and
Can genetic hair loss be treated?
Yes genetic hair loss can be treated if the treatment is started in time. Heredity hair loss usually runs in the family and can affect both men and women. If you too have a close elder relative who lost his or hair in a patterned baldness then you should keep a close eye on your hair too. Hereditary hair loss usually happens in a pattern; M or W shaped in men and along the hair part in women. See the doctor immediately if you suffer from hair loss. There are many common and successful treatments available for genetic hair loss which include
- Topical and oral medications: These include Minoxidil topical lotion and Finasteride tablets.
- Hair transplantation using FUT and FUE methods.
- Nutritional supplements: Your physician might also suggest some hair supplements that can help arrest hair fall. Dietary supplements containing Vitamin A, C, and Biotin, zinc, and iron can also help control hair fall caused because of genetics.
Treatment option for Chemotherapy induced Alopecia?
Alopecia post chemotherapy is a very common consequence of cancer treatments and therapies and it is often the most psychologically and socially devastating side effect. Many patients shy away from the treatments because of fear of hair fall and hair loss. However, in most cases, such alopecia is reversible but the recovery takes several months and even up to a year. Some basic latest treatment methods will speed up the healing:
- Scalp Cooling: This is a FDA approved method for patients suffering from breast cancer. Scalp cooling or hypothermia results in constriction of the blood vessels in the scalp, which in turn leads to reduced delivery of chemotherapy to the hair. Scalp cooling devices consist of cooling unit that circulate the coolant on the scalp. This is done about 30 minutes before the start of chemotherapy. Patients can feel some mild discomfort, nausea, and dry skin because of scalp cooling.
- Topical Minoxidil: Minoxidil helps by increasing the blood flow to the hair follicle thereby preventing miniaturization of hair follicle.
- QR678® hair regrowth treatment: QR678® is a FDA approved, completely safe hair regrowth treatment that has no side effects or causes any discomfort to the patient. Clinical trials have proved QR678 to be effective in treatment of chemotherapy induced alopecia in both men and women. The results of QR678® last lifelong.